We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Urine Test Allows for Rapid Preeclampsia Diagnosis

By LabMedica International staff writers
Posted on 27 Mar 2019
Hypertensive disorders affect 15% of pregnancies and account for one quarter of the antenatal admissions. More...
Preeclampsia (PE) is a multisystem disorder specific to human pregnancy, and its incidence varies from 5% to 60% of gestations, depending on maternal co-morbidities.

PE has a large spectrum of medical signs and symptoms resulting in a range of clinical phenotypes and outcomes, making a diagnosis on available clinical and laboratory parameters challenging. Hypertension and proteinuria are non-specific, and thus major challenges arise when differential diagnosis includes chronic hypertension, endocrine, and kidney diseases.

Scientists at The Ohio State University College of Medicine (Columbus, OH, USA) recruited 346 consecutive pregnant patients from the labor and delivery (L&D) triage unit at Wexner Medical Center (Columbus, OH, USA) and followed prospectively until delivery from July 2014 to July 2015. Eligible, consenting women were approached for enrollment by certified research nurses immediately after their presentation to the triage area before initiation of the clinical work-up for PE. The team designed, developed and validated a simple bedside, paper-based urine test kit, which they named the CR Dot (CRD) Paper Test.

Of the approached women, 353 (98%) agreed to participate. Patients were consented to provide a urine and matched venous blood sample. Refusal to provide a blood sample by 107 women was not an exclusion criterion. Urine was collected in sterile containers and tested fresh without processing in the triage area. The result of the CRD Paper Test was read at three minutes. The team used immunoassays to measure levels of urine and serum soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF). The sFlt-1/PlGF ratios were calculated and used for comparison with the results of the CRD Paper Test.

The team reported that 89 of the pregnant women had a clinical diagnosis of preeclampsia. Of those, 79% were induced due to preeclampsia, with an average age of delivery at 33 weeks gestation. The team found the CRD test was superior to the other biochemical tests, with an accuracy rate of 86%. Urine congophilia was detected in 14 (12%) patients admitted with an uncertain diagnosis and in only 59 (58%) patients admitted with a diagnosis of PE established or confirmed in triage. There were nine (8%) instances of positive congophilia in the group of patients discharged home absent PE. The CRD Paper Test was positive in just four (36%) patients discharged with a diagnosis of PE.

Kara M. Rood, MD, a maternal-fetal medicine physician and first author of the study, said, “This is the first clinical study using the point-of-care, paper-based Congo Red Dot (CRD) diagnostic test, and the mechanism proved superior in establishing or ruling out a diagnosis of preeclampsia. Our findings will have a huge impact on the health of women and children.” The study was published on March 1, 2019, in the journal EClinicalMedicine.

Related Links:
The Ohio State University College of Medicine
Wexner Medical Center


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.